A groundbreaking cancer injection developed by Johnson & Johnson has delivered what researchers are calling "unprecedented" results in a major clinical trial spanning 11 nations. The drug, known as amivantamab, was tested on 102 patients suffering from head and neck cancer whose disease had either spread or returned after other treatments failed.
Remarkable Tumour Reduction
The trial reported that tumours shrank in over a third of participants, with 15 patients experiencing complete eradication of their tumours. This outcome is particularly striking given the advanced stage of the cancers involved. Patients receiving amivantamab lived for a median of 12.5 months after starting treatment, despite having cancers with poor prognoses.
How the Drug Works
Amivantamab targets a specific protein that aids tumour growth, effectively blocking a pathway used by cancer cells to resist treatment. Additionally, it activates the body's immune system to assist in fighting the cancer. This dual mechanism of action is believed to be responsible for its impressive efficacy.
One patient, Carl Walsh, expressed significant satisfaction with his progress, noting a marked improvement in his condition. The promising findings are scheduled to be presented at the American Society of Clinical Oncology annual meeting in Chicago.
Ongoing Research
Beyond head and neck cancer, amivantamab is currently undergoing testing in approximately 60 other clinical trials for various cancers, including lung, colorectal, brain, and gastric types. Researchers are optimistic that this injection could revolutionize treatment for multiple forms of the disease.
